Provided by Tiger Trade Technology Pte. Ltd.

Tiziana Life Sciences PLC

1.36
+0.09007.09%
Post-market: 1.33-0.0300-2.21%19:59 EST
Volume:230.08K
Turnover:309.36K
Market Cap:172.72M
PE:-11.90
High:1.39
Open:1.28
Low:1.27
Close:1.27
52wk High:2.60
52wk Low:0.6333
Shares:127.00M
Float Shares:68.78M
Volume Ratio:1.01
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1143
EPS(LYR):-0.1112
ROE:-232.31%
ROA:-83.78%
PB:18.77
PE(LYR):-12.23

Loading ...

Company Profile

Company Name:
Tiziana Life Sciences PLC
Exchange:
NASDAQ
Establishment Date:
1998
Employees:
9
Office Location:
14/15 Conduit Street,London,Greater London,United Kingdom
Zip Code:
W1S 2XJ
Fax:
- -
Introduction:
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Directors

Name
Position
Gabriele Marco Antonio Cerrone
Executive Chairman
Ivor Elrifi
Executive Director and Chief Executive Officer
John Brancaccio
Non-Executive Director
Willy Simon
Non-Executive Director

Shareholders

Name
Position
Ivor Elrifi
Executive Director and Chief Executive Officer
Keeren Shah
Chief Financial Officer and Chief Operating Officer
William Clementi
Chief Development Officer